Table 3 Summary studies for the association between NAFLD and cholangiocarcinoma and breast cancer
Study | Country | Sample size | NAFLD diagnosis | Patients source | Date | Study design | Cancer diagnosis | Adjusted confounding factors | Study quality |
|---|---|---|---|---|---|---|---|---|---|
Cholangiocarcinoma | |||||||||
Petrick et al. 2017 [41] | US | 328,688 | ICD-9 | Community | 2000–2011 | Case-control | ICD-9 | Age, race/ethnicity, geographic region, and state buy-in status | Good |
Choi et al. 2016 [38] | US | 7164 | Histology/Imaging | Hospital | 2000–2014 | Case-control | ICD-9 | The differences in frequencies of aspirin current users | Good |
Kinoshita et al. 2016 [39] | Japan | 103 | Histology | Hospital | 1995–2014 | Case-control | Pathology | NA | Fair |
Stepien et al. 2016 [42] | Europe | 495 | Hepatic steatosis index | Community | 1992–2000 | Case-control | ICD-9 | Smoking status, baseline, lifetime alcohol intake pattern, body mass index, physical activity, hepatitis B, C infection, diabetes status, CRP | Good |
Lee et al. 2015 [40] | South Korea | 243 | Histology/Imaging | Hospital | 2007–2013 | Case-control | Pathology | NA | Good |
Chang et al. 2013 [37] | China | 25,785 | ICD-9 | Community | 2004–2008 | Case-control | ICD-9 | Possible intermediate factors | Fair |
Welzel et al. 2007 [43] | US | 103,866 | ICD-9 | Community | 1999–2009 | Case-control | ICD-9 | NA | Fair |
Breast cancer | |||||||||
Allen et al. 2019 [21] | USA | 676 | ICD-9 | Community | 1997–2016 | Cohort | ICD-9 | NA | Good |
Kim et al. 2017 [24] | Korea | NA | Ultrasonography | Community | 2004–2005 | Cohort | Pathology radiology | Demographic and metabolic factors | Good |
Nseir et al. 2017 [45] | Israel | 146 | Ultrasonography | Community | 2008–2011 | Cohort | Ultrasonography | NA | Good |
Kwak et al. 2019 [44] | USA | 540 | Ultrasonography. | Community | 2008–2017 | Case-control | Ultrasonography | NA | Good |